Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities:
Net loss	$ (785,104)	$ (357,735)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	70,203	57,000
Amortization of debt discount	0	50,452
Amortization of debt issuance costs	4,375	150,992
Stock compensation Expense	303,797	88,595
Change in fair value of derivative instruments	71,398	18,286
Change in marketable securities	(109,791)	(12,570)
Benefit from deferred income taxes	(128,536)	0
Gain from the sale of Product Line	0	(499,529)
Change in assets and liabilities
Accounts receivable	(718,019)	(65,357)
Notes receivable	(1,066)	8,892
Inventories	(332,813)	(443,098)
Prepaid expenses	(581,336)	(47,979)
Deposits and other assets	(16,386)	351,412
Trade accounts payable	591,743	(160,980)
Accrued expenses	(95,375)	(22,479)
Deferred Revenues	266,032	0
Income taxes	0	54,841
Net cash used in operating activities	(1,460,878)	(829,257)
Cash flows from investing activities:
Purchase of property and equipment	(119,194)	(60,991)
Proceeds from the sale of Product Line	0	500,000
Proceeds for the sale of marketable securities	26,919	0
Redemption of Investments	965,886	0
Net cash provided in investing activities	873,611	439,009
Cash flows from financing activities:
Proceeds from notes payable	25,101	0
Payment of notes payable	(3,482)	(766,807)
Payment of vendor notes	0	(1,000)
Proceeds from line of credit	0	4,547,857
Repayment of line of credit	(50,000)	(4,695,508)
Proceeds from exercise of warrants	334	0
Deferred offering costs	0	(767,507)
Cash acquired in merger	0	4,498,430
Distributions to shareholder	0	(364,406)
Net cash (used in) provided by financing activities	(28,047)	2,451,059
Net increase (decrease) in cash	(615,314)	2,060,811
Cash and cash equivalents, beginning of period	1,655,453	364,608
Cash and cash equivalents, end of period	1,040,139	2,425,419
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	37,049	206,341
Non-cash transactions
Conversion of notes payable to common stock	0	250,000
Decrease in warrant derivative liability due to warrant exercise	87,755	0
Decrease in deferred tax asset due to warrant exercise	33,355	0
Cashless exercise of options	600	0
Cashless exercise of warrants	$ 1,555	$ 0